HK1255328A1 - 與清除顆粒相關的組合物和方法 - Google Patents
與清除顆粒相關的組合物和方法Info
- Publication number
- HK1255328A1 HK1255328A1 HK18114464.8A HK18114464A HK1255328A1 HK 1255328 A1 HK1255328 A1 HK 1255328A1 HK 18114464 A HK18114464 A HK 18114464A HK 1255328 A1 HK1255328 A1 HK 1255328A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- scavanger
- compositions
- particles
- methods related
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186838P | 2015-06-30 | 2015-06-30 | |
US201562198541P | 2015-07-29 | 2015-07-29 | |
US201562198519P | 2015-07-29 | 2015-07-29 | |
US201562236507P | 2015-10-02 | 2015-10-02 | |
US201662319092P | 2016-04-06 | 2016-04-06 | |
PCT/US2016/040022 WO2017004159A1 (en) | 2015-06-30 | 2016-06-29 | Compositions and methods related to scavanger particles |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1255328A1 true HK1255328A1 (zh) | 2019-08-16 |
Family
ID=57609422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18114464.8A HK1255328A1 (zh) | 2015-06-30 | 2018-11-13 | 與清除顆粒相關的組合物和方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180256747A1 (zh) |
EP (1) | EP3316864A4 (zh) |
JP (3) | JP7370691B2 (zh) |
KR (1) | KR20180043785A (zh) |
CN (4) | CN108135848A (zh) |
AU (2) | AU2016285868B2 (zh) |
BR (1) | BR112017028315A2 (zh) |
CA (1) | CA2991142A1 (zh) |
EA (1) | EA201890170A1 (zh) |
HK (1) | HK1255328A1 (zh) |
IL (2) | IL256445B2 (zh) |
MX (3) | MX2017017051A (zh) |
MY (1) | MY198240A (zh) |
SG (1) | SG10201913518XA (zh) |
WO (1) | WO2017004159A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3215176A4 (en) | 2014-10-03 | 2018-05-23 | Ntercept, LLC | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
KR20180034619A (ko) * | 2015-07-29 | 2018-04-04 | 나노틱스 엘엘씨 | 가용성 생체분자를 소거하기 위한 모듈 조성물 및 이와 관련된 방법 |
WO2017136356A2 (en) * | 2016-02-01 | 2017-08-10 | Emory University | Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting |
WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
EP3565604A4 (en) * | 2017-01-04 | 2020-09-09 | Nanotics, LLC | ELIMINATING PARTICLE ASSEMBLY PROCESSES |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
CN108404118A (zh) * | 2017-06-14 | 2018-08-17 | 张建宁 | 人源乳凝集素亚型蛋白的新用途 |
EP3477305A1 (en) | 2017-10-25 | 2019-05-01 | Universität Heidelberg | Delta-like ligand 1 for diagnosing severe infections |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
FR3094268B1 (fr) * | 2019-03-28 | 2021-03-19 | Carbiolice | Article multicouche enzymé |
ES2932081T3 (es) * | 2019-04-15 | 2023-01-11 | Nanologica Ab | Partículas porosas vacías para su uso en el tratamiento, la prevención y/o el retraso de la degeneración de enfermedades neurodegenerativas, neuronas y glía |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
EP3986429A4 (en) * | 2019-06-21 | 2023-07-19 | Entelexo Biotherapeutics Inc. | PLATFORMS, COMPOSITIONS AND METHODS OF DELIVERING THERAPEUTIC COMPOUNDS |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
WO2021231436A1 (en) * | 2020-05-11 | 2021-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic methods for treating covid-19 infections |
CN111575388B (zh) * | 2020-06-02 | 2022-10-21 | 江汉大学 | PfHMGB1作为藻毒素侵害的分子标志物的应用及检测试剂盒 |
CN112264115B (zh) * | 2020-10-26 | 2022-03-11 | 南京鼓楼医院 | 一种搭载分子印迹反蛋白石结构微球的鱼骨微流控芯片及其制备方法 |
CN113358617B (zh) * | 2021-06-02 | 2024-03-01 | 重庆大学 | 胞外囊泡富集检测方法 |
KR20230023442A (ko) | 2021-08-10 | 2023-02-17 | 현대자동차주식회사 | 차량의 차체 |
CN114128723B (zh) * | 2021-11-09 | 2023-07-04 | 苏州大学 | 一种抗病毒纳米材料及其应用 |
JP7368766B2 (ja) | 2022-03-02 | 2023-10-25 | 株式会社リコー | 情報処理装置、情報処理システム、情報処理方法およびプログラム |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
CN101123990A (zh) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒,和免疫原性结构 |
WO2006086428A2 (en) * | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Particles for inactivating toxins |
EP2033660A1 (en) | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
WO2010042555A2 (en) * | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
US20120108787A1 (en) * | 2009-02-26 | 2012-05-03 | Nubiome, Inc. | Immobilization Particles for Removal of Microorganisms and/or Chemicals |
EP2714017B1 (en) | 2011-06-02 | 2018-08-01 | The Regents of The University of California | Membrane encapsulated nanoparticles and method of use |
CA2883080A1 (en) * | 2011-08-26 | 2013-03-07 | Vecoy Nanomedicines Ltd. | Pathogen and substance traps |
US20140220133A1 (en) * | 2012-11-28 | 2014-08-07 | Cytimmune Sciences, Inc. | Nanotechnology Based Medicine for Biodefense |
US20170038382A1 (en) * | 2014-01-24 | 2017-02-09 | Ntercept, Llc | Methods and compositions for immune dis-inhibition |
EP3215176A4 (en) * | 2014-10-03 | 2018-05-23 | Ntercept, LLC | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
-
2016
- 2016-06-29 CN CN201680049849.5A patent/CN108135848A/zh active Pending
- 2016-06-29 CN CN202111385729.1A patent/CN114129737A/zh active Pending
- 2016-06-29 IL IL256445A patent/IL256445B2/en unknown
- 2016-06-29 EA EA201890170A patent/EA201890170A1/ru unknown
- 2016-06-29 AU AU2016285868A patent/AU2016285868B2/en active Active
- 2016-06-29 MX MX2017017051A patent/MX2017017051A/es unknown
- 2016-06-29 BR BR112017028315A patent/BR112017028315A2/pt active Search and Examination
- 2016-06-29 CN CN202310869623.1A patent/CN116763941A/zh active Pending
- 2016-06-29 KR KR1020187002793A patent/KR20180043785A/ko not_active Application Discontinuation
- 2016-06-29 EP EP16818651.8A patent/EP3316864A4/en active Pending
- 2016-06-29 CN CN202310865497.2A patent/CN116785457A/zh active Pending
- 2016-06-29 JP JP2017568165A patent/JP7370691B2/ja active Active
- 2016-06-29 US US15/738,954 patent/US20180256747A1/en active Pending
- 2016-06-29 WO PCT/US2016/040022 patent/WO2017004159A1/en active Application Filing
- 2016-06-29 IL IL297460A patent/IL297460A/en unknown
- 2016-06-29 MY MYPI2017001935A patent/MY198240A/en unknown
- 2016-06-29 CA CA2991142A patent/CA2991142A1/en active Pending
- 2016-06-29 SG SG10201913518XA patent/SG10201913518XA/en unknown
-
2017
- 2017-12-20 MX MX2023005261A patent/MX2023005261A/es unknown
- 2017-12-20 MX MX2023005262A patent/MX2023005262A/es unknown
-
2018
- 2018-11-13 HK HK18114464.8A patent/HK1255328A1/zh unknown
-
2021
- 2021-10-29 JP JP2021177516A patent/JP2022031665A/ja not_active Withdrawn
-
2022
- 2022-01-14 AU AU2022200233A patent/AU2022200233B2/en active Active
-
2023
- 2023-07-13 JP JP2023114971A patent/JP2023153813A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG10201913518XA (en) | 2020-02-27 |
JP2023153813A (ja) | 2023-10-18 |
BR112017028315A2 (pt) | 2018-09-04 |
US20180256747A1 (en) | 2018-09-13 |
AU2022200233B2 (en) | 2024-05-30 |
MX2017017051A (es) | 2018-05-15 |
JP7370691B2 (ja) | 2023-10-30 |
IL256445A (en) | 2018-04-30 |
IL256445B2 (en) | 2023-03-01 |
CN108135848A (zh) | 2018-06-08 |
JP2018524344A (ja) | 2018-08-30 |
AU2016285868A1 (en) | 2018-02-01 |
WO2017004159A1 (en) | 2017-01-05 |
CN114129737A (zh) | 2022-03-04 |
MX2023005261A (es) | 2023-05-23 |
KR20180043785A (ko) | 2018-04-30 |
EP3316864A4 (en) | 2019-03-06 |
JP2022031665A (ja) | 2022-02-22 |
MX2023005262A (es) | 2023-05-23 |
AU2016285868B2 (en) | 2021-11-11 |
CN116785457A (zh) | 2023-09-22 |
EA201890170A1 (ru) | 2018-07-31 |
IL297460A (en) | 2022-12-01 |
CN116763941A (zh) | 2023-09-19 |
CA2991142A1 (en) | 2017-01-05 |
AU2022200233A1 (en) | 2022-02-10 |
EP3316864A1 (en) | 2018-05-09 |
MY198240A (en) | 2023-08-16 |
IL256445B (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255328A1 (zh) | 與清除顆粒相關的組合物和方法 | |
IL273205A (en) | Preparations and methods | |
IL249011A0 (en) | Methods and preparations related to exosomes | |
EP3397261A4 (en) | METHODS AND COMPOSITIONS RELATING TO THE CHONDRISOMES | |
GB2546350B (en) | Compositions and methods | |
HK1218837A1 (zh) | 組合物和方法 | |
HK1218560A1 (zh) | 組成與方法 | |
GB2535253B (en) | Compositions and methods | |
GB2520795B (en) | Compositions and methods | |
HK1214171A1 (zh) | 賽尼克韋羅組合物及其製備和使用方法 | |
GB201308072D0 (en) | Compositions and methods | |
GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
GB201417828D0 (en) | New methods and compositions | |
GB201305813D0 (en) | Compositions and methods | |
EP2964610A4 (en) | VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF | |
HUE055062T2 (hu) | Készítmények és eljárások csontképzõdés elõsegítésére | |
GB201512996D0 (en) | Compositions and methods | |
GB201514413D0 (en) | Compositions and methods | |
GB201402915D0 (en) | Compositions and methods | |
IL256261B (en) | Hide1 compositions and methods | |
GB201521306D0 (en) | Compositions comprising nanoparticles and methods thereof | |
GB201522554D0 (en) | Methods and compositions | |
GB201518167D0 (en) | Methods and compositions | |
GB201514415D0 (en) | Compositions and methods | |
GB201403212D0 (en) | Compositions and methods |